Brief: Initiator Pharma Completes Preclinical Studies For Development Of Candidate IPED2015
Jan 22 (Reuters) - INITIATOR PHARMA A/S INIT.TE :
* SUCCESFULLY COMPLETES PRECLINICAL STUDIES FOR DEVELOPMENT
OF
CANDIDATE IPED2015
* IT IS ANTICIPATED THAT IPED2015 WILL QUALIFY AS A CLINICAL
CANDIDATE
Source text for Eikon: ID:nWkr81jkpk
Further company coverage: INIT.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Initiator Pharma A/S
See all newsBrief: Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
Brief: Initiator Pharma To Fully Prioritize Pudafensine
Brief: Initiator Pharma Reports Q4 Net Revenue Of DKK 0.00
Brief: Initiator Pharma Q4 Operating Loss Widens To DKK 7 Mln
Brief: Initiator Pharma Granted European Patent For Pudafensine in FSD